Skip to main content
SpringerLink
Log in

HSP90B1 overexpression predicts poor prognosis in NSCLC patients

  • Original Article
  • Published:
Tumor Biology

Abstract

Non-small cell lung cancer (NSCLC) accounts for 85 % of lung cancer-related mortality worldwide. The heat shock protein 90B1 (HSP90B1) and DNA damage-inducible transcript 3 (DDIT3) are endoplasmic reticulum stress-related proteins that are associated with many malignancies. However, the roles of two proteins on NSCLC remain uncovered. To investigate the correlation between the expressions of HSP90B1 and DDIT3 and clinicopathological parameters of NSCLC as well as the significance of prognosis in NSCLC, a total of 143 NSCLC tissue samples and 45 control tissues samples were assessed. NSCLC patients were followed up from the day of surgery and ended by March 2014. The expressions of HSP90B1 and DDIT3 proteins were detected in all paraffin-embedded biopsy samples by immunochemistry. The HSP90B1 was highly expressed (65.2 %) in the 143 NSCLC patients, and its high expression was correlated with clinical stages (P = 0.001) and lymph node metastasis (P = 0.016). Similarly, DDIT3 was highly expressed in 43 (30.1 %) of 143 NSCLC patients, but only correlated with lymph node metastasis. Furthermore, Log-rank test suggested that high HSP90B1 expression may predict shorter survival (overall survival (OS)) and disease-free survival (DFS) for NSCLC patients. Cox model multivariate analyses indicated that HSP90B1 overexpression was an independent poor prognostic factor for both of OS and DFS. Therefore, HSP90B1 and DDIT3 may the potential biomarker to predict the NSCLC clinicopathological progress. Meanwhile, high HSP90B1 expression means poor prognosis, and HSP90B1 can be a promising prognosis factor for NSCLC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Alberg AJ, Brock MV, Ford JG, Samet JM, Spivack SD. Epidemiology of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e1S–e29S.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Zinner R, Visseren-Grul C, Spigel DR, Obasaju C. Pemetrexed clinical studies in performance status 2 patients with non-small cell lung cancer. Int J Oncol. 2016;48(1):13–27.

    CAS  PubMed  Google Scholar 

  3. Chen B, Piel WH, Gui L, Bruford E, Monteiro A. The HSP90 family of genes in the human genome: insights into their divergence and evolution. Genomics. 2005;86(6):627–37.

    Article  CAS  PubMed  Google Scholar 

  4. Li M, Xiao T, Zhang Y, Feng L, Lin D, Liu Y, et al. Prognostic significance of matrix metalloproteinase-1 levels in peripheral plasma and tumour tissues of lung cancer patients. Lung Cancer. 2010;69(3):341–7.

    Article  PubMed  Google Scholar 

  5. Yang Z, Zhuang L, Szatmary P, Wen L, Sun H, Lu Y, et al. Upregulation of heat shock proteins (HSPA12A, HSP90B1, HSPA4, HSPA5, and HSPA6) in tumour tissues is associated with poor outcomes from HBV-related early-stage hepatocellular carcinoma. Int J Med Sci. 2015;12(3):256–63.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Zheng HC, Takahashi H, Li XH, Hara T, Masuda S, Guan YF, et al. Overexpression of GRP78 and GRP94 are markers for aggressive behavior and poor prognosis in gastric carcinomas. Hum Pathol. 2008;39(7):1042–9.

    Article  CAS  PubMed  Google Scholar 

  7. Langer R, Feith M, Siewert JR, Wester HJ, Hoefler H. Expression and clinical significance of glucose regulated proteins GRP78 (BiP) and GRP94 (GP96) in human adenocarcinomas of the esophagus. BMC Cancer. 2008;8:70.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Takahashi H, Wang JP, Zheng HC, Masuda S, Takano Y. Overexpression of GRP78 and GRP94 is involved in colorectal carcinogenesis. Histol Histopathol. 2011;26(6):663–71.

    PubMed  Google Scholar 

  9. Bi M, Naczki C, Koritzinsky M, Fels D, Blais J, Hu N, et al. ER stress-regulated translation increases tolerance to extreme hypoxia and promotes tumor growth. EMBO J. 2005a;24(19):3470–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Tsim S, O’ Dowd CA, Milroy R, Davidson S. Staging of non-small cell lung cancer (NSCLC): a review. Respir Med. 2010;104(12):1767–74.

    Article  CAS  PubMed  Google Scholar 

  11. Maximus S, Nguyen DV, Mu Y, Calhoun RF, Cooke DT. Size of stage IIIA primary lung cancers and survival: a surveillance, epidemiology and end results database analysis. Am Surg. 2012;78(11):1232–7.

    PubMed  Google Scholar 

  12. Xu Y, Chen Z, Zhang G, Xi Y, Sun R, Chai F, et al. HMGB1 overexpression correlates with poor prognosis in early-stage squamous cervical cancer. Tumor Biol. 2015;36(11):9039–47.

    Article  CAS  Google Scholar 

  13. Soumaoro LT, Uetake H, Higuchi T, Takagi Y, Enomoto M, Sugihara K. Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res. 2004;10(24):8465–71.

    Article  CAS  PubMed  Google Scholar 

  14. Kaemmerer D, Peter L, Lupp A, Schulz S, Sänger J, Baum RP, et al. Comparing of IRS and Her2 as immunohistochemical scoring schemes in gastroenteropancreatic neuroendocrine tumors. Int J Clin Exp Pathol. 2012;5(3):187–94.

    PubMed  PubMed Central  Google Scholar 

  15. She J, Yang P, Hong Q, Bai C. Lung cancer in China: challenges and interventions. Chest. 2013;143(4):1117–26.

    Article  PubMed  Google Scholar 

  16. Chen W, Zheng R, Zeng H, Zhang S. Epidemiology of lung cancer in China. Thorac Cancer. 2015;6(2):209–15.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32.

    Article  PubMed  Google Scholar 

  18. Dubey A, Prajapati KS, Swamy M, Pachauri V. Heat shock proteins: a therapeutic target worth to consider. Vet World. 2015;8(1):46–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Marcinak SJ, Ron D. The unfolded protein response in lung disease. Proc Am Thorac Soc. 2010;7(6):356–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Kato H, Nishitoh H. Stress responses from the endoplasmic reticulum in cancer. Front Oncol. 2015;5:93.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Yang Y, Li Z. Roles of heat shock protein gp96 in the ER quality control: redundant or unique function? Mol Cells. 2005;20(2):173–82.

    Article  CAS  PubMed  Google Scholar 

  22. Lee JH, Kang KW, Kim JE, Hwang SW, Park JH, Kim SH, et al. Differential expression of heat shock protein 90 isoforms in small cell lung cancer. Int J Clin Exp Pathol. 2015;8(8):9487–93.

    PubMed  PubMed Central  Google Scholar 

  23. Kim YS, Alarcon SV, Lee S, Lee MJ, Glaccone G, Neckers L, et al. Update on Hsp90 inhibitors in clinical trial. Curr Top Med Chem. 2009;9(15):1479–92.

    Article  CAS  PubMed  Google Scholar 

  24. Ueno T, Tsukuda K, Toyooka S, Ando M, Takaoka M, Soh J, et al. Strong anti-tumor effect of NVP-AUY922, a novel Hsp90 inhibitor, on non-small cell lung cancer. Lung Cancer. 2012;76(1):26–31.

    Article  PubMed  Google Scholar 

  25. Jhaveri K, Taldone T, Modi S, Chiosis G. Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim Biophys Acta. 2012;1823(3):742–55.

    Article  CAS  PubMed  Google Scholar 

  26. Kim KM, TK Y, Chu HH, Park HS, Jang KY, Moon WS, et al. Expression of ER stress and autophagy-related molecules in human non-small cell lung cancer and premalignant lesions. Int J Cancer. 2012;131(4):E362–70.

    Article  CAS  PubMed  Google Scholar 

  27. Lee CY, Lee MG, Choi KC, Kang HM, Chang YS. Clinical significance of GADD153 expression in stage I non-small cell lung cancer. Oncol Lett. 2012;4(3):408–12.

    PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

This work was supported by the Natural Science Foundation of Shanxi Science and Technology Department (2012011038-4) and by the Intramural Research Program of Fenyang College of Shanxi Medical University.

Author information

Authors and Affiliations

  1. Department of Pathology, Shanxi Medical University FenYang College, Fenyang, Shanxi Province, 032200, China

    YiRong Xu, ZhenWen Chen, GuangHeng Zhang, XiaoGang Wang, WenYan Wang, Fei Chai & XiongFeng Li

  2. Department of Pathology, Shanxi Tumor Hospital (Shanxi Institute of Oncology), Taiyuan, Shanxi Province, 030000, China

    YanFeng Xi & RuiFang Sun

Authors
  1. YiRong Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. ZhenWen Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. GuangHeng Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. YanFeng Xi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. RuiFang Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. XiaoGang Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. WenYan Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Fei Chai
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. XiongFeng Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to ZhenWen Chen.

Ethics declarations

Conflicts of interest

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xu, Y., Chen, Z., Zhang, G. et al. HSP90B1 overexpression predicts poor prognosis in NSCLC patients. Tumor Biol. 37, 14321–14328 (2016). https://doi.org/10.1007/s13277-016-5304-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-016-5304-7

Keywords

Search

Navigation